BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 16169076)

  • 1. Opioids and differentiation in human cancer cells.
    Zagon IS; McLaughlin PJ
    Neuropeptides; 2005 Oct; 39(5):495-505. PubMed ID: 16169076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioids and migration, chemotaxis, invasion, and adhesion of human cancer cells.
    Zagon IS; Rahn KA; McLaughlin PJ
    Neuropeptides; 2007 Dec; 41(6):441-52. PubMed ID: 17910895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
    Zagon IS; McLaughlin PJ
    Int J Oncol; 2004 Jun; 24(6):1443-8. PubMed ID: 15138586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Opioids and the apoptotic pathway in human cancer cells.
    Zagon IS; McLaughlin PJ
    Neuropeptides; 2003 Apr; 37(2):79-88. PubMed ID: 12747939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reepithelialization of the human cornea is regulated by endogenous opioids.
    Zagon IS; Sassani JW; McLaughlin PJ
    Invest Ophthalmol Vis Sci; 2000 Jan; 41(1):73-81. PubMed ID: 10634604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nucleocytoplasmic distribution of opioid growth factor and its receptor in tongue epithelium.
    Zagon IS; Ruth TB; McLaughlin PJ
    Anat Rec A Discov Mol Cell Evol Biol; 2005 Jan; 282(1):24-37. PubMed ID: 15584033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid growth factor inhibits intimal hyperplasia in balloon-injured rat carotid artery.
    Zagon IS; Essis FM; Verderame MF; Healy DA; Atnip RG; McLaughlin PJ
    J Vasc Surg; 2003 Mar; 37(3):636-43. PubMed ID: 12618704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T lymphocyte proliferation is suppressed by the opioid growth factor ([Met(5)]-enkephalin)-opioid growth factor receptor axis: implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011 May; 216(5):579-90. PubMed ID: 20965606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-dose naltrexone targets the opioid growth factor-opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model.
    Donahue RN; McLaughlin PJ; Zagon IS
    Exp Biol Med (Maywood); 2011 Sep; 236(9):1036-50. PubMed ID: 21807817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice.
    Donahue RN; McLaughlin PJ; Zagon IS
    Gynecol Oncol; 2011 Aug; 122(2):382-8. PubMed ID: 21531450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
    Zagon IS; Verderame MF; Hankins J; McLaughlin PJ
    Int J Oncol; 2007 Apr; 30(4):775-83. PubMed ID: 17332915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opioid growth factor enhances tumor growth inhibition and increases the survival of paclitaxel-treated mice with squamous cell carcinoma of the head and neck.
    Jaglowski JR; Zagon IS; Stack BC; Verderame MF; Leure-duPree AE; Manning JD; McLaughlin PJ
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):97-104. PubMed ID: 15791460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opioid growth factor inhibition of a human squamous cell carcinoma of the head and neck in nude mice: dependency on the route of administration.
    McLaughlin PJ; Stack BC; Braine KM; Ruda JD; Zagon IS
    Int J Oncol; 2004 Jan; 24(1):227-32. PubMed ID: 14654962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer.
    Cheng F; Zagon IS; Verderame MF; McLaughlin PJ
    Cancer Res; 2007 Nov; 67(21):10511-8. PubMed ID: 17974995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced growth inhibition of squamous cell carcinoma of the head and neck by combination therapy of paclitaxel and opioid growth factor.
    McLaughlin PJ; Jaglowski JR; Verderame MF; Stack BC; Leure-Dupree AE; Zagon IS
    Int J Oncol; 2005 Mar; 26(3):809-16. PubMed ID: 15703840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opioid growth factor regulates the cell cycle of human neoplasias.
    Zagon IS; Roesener CD; Verderame MF; Ohlsson-Wilhelm BM; Levin RJ; McLaughlin PJ
    Int J Oncol; 2000 Nov; 17(5):1053-61. PubMed ID: 11029512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.
    Wang R; Zhang Y; Shan F
    Int Immunopharmacol; 2019 Oct; 75():105785. PubMed ID: 31404891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The opioid growth factor, [Met5]-enkephalin, and the zeta opioid receptor are present in human and mouse skin and tonically act to inhibit DNA synthesis in the epidermis.
    Zagon IS; Wu Y; McLaughlin PJ
    J Invest Dermatol; 1996 Mar; 106(3):490-7. PubMed ID: 8648182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homeostasis of ocular surface epithelium in the rat is regulated by opioid growth factor.
    Zagon IS; Sassani JW; Kane ER; McLaughlin PJ
    Brain Res; 1997 Jun; 759(1):92-102. PubMed ID: 9219867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. B lymphocyte proliferation is suppressed by the opioid growth factor-opioid growth factor receptor axis: Implication for the treatment of autoimmune diseases.
    Zagon IS; Donahue RN; Bonneau RH; McLaughlin PJ
    Immunobiology; 2011; 216(1-2):173-83. PubMed ID: 20598772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.